Corticobasal Degeneration News and Research

RSS

Scientists traced a hidden immune route that may worsen tau-linked brain damage

In a mouse model of tauopathy, conventional type 1 dendritic cells (cDC1s) cross-presented brain-derived antigens in deep cervical lymph nodes, priming CD8+ T cells that accumulated in the brain and promoted neurodegeneration. Disrupting cDC1s or their cross-presentation activity reduced CD8+ T-cell infiltration and protected against neuronal loss, while human primary tauopathy samples also showed increased brain CD8+ T cells, although cDC1 involvement in humans remains unconfirmed.

6 Sep 2026

Advanced use of MRI aids in accurate identification of rare, atypical parkinsonian disorders

An international study led by researchers from the Sant Pau Research Institute (IR Sant Pau) shows that advanced use of magnetic resonance imaging (MRI) allows much more accurate identification of patients with progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD).

16 Feb 2026

New molecular ruler enables precise measurement of toxic Tau fibrils in fluid samples

Researchers have developed a new tool, FibrilPaint combined with the FibrilRuler test, that allows scientists to directly measure the length of toxic Tau amyloid fibrils in tiny fluid samples, from the earliest aggregation stages to mature fibrils and even at very low concentrations.

11 Dec 2025

Synthetic tau protein reveals key insights into protein misfolding and fibril formation

Scientists at Northwestern University and University of California, Santa Barbara have created the first synthetic fragment of tau protein that acts like a prion.

29 Apr 2025

U.S. launches national plan to tackle Parkinson's disease and related disorders

With support from the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Health (OASH), the National Institutes of Health (NIH) is leading the implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinson's Act (P.L. 118-66), which was signed into law on July 2, 2024.

17 Jan 2025

New biomarker could help predict Parkinson’s disease progression

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

12 Nov 2024

New study identifies potential treatment for tauopathies using carbonic anhydrase inhibitors

Carbonic anhydrase inhibitors show potential in reducing tau protein buildup, offering new therapeutic avenues for neurodegenerative diseases like tauopathies.

4 Nov 2024

New compound shows promise in Alzheimer’s preclinical models

A multidisciplinary team of scientists led by Kurt Brunden, Ph.D., at the University of Pennsylvania Perelman School of Medicine, and Carlo Ballatore, Ph.D., at University of California San Diego, has been awarded a $6.9 million grant from the National Institute on Aging (NIA) to prepare a potential disease-modifying Alzheimer's treatment for future clinical trials.

21 Aug 2024

NIH awards $6.9 million to prepare a potential Alzheimer's treatment for future clinical trials

A multidisciplinary team of scientists led by Carlo Ballatore, Ph.D., at University of California San Diego and Kurt Brunden, Ph.D., at the University of Pennsylvania has been awarded a $6.9 million grant from the National Institute on Aging (NIA) to prepare a potential disease-modifying Alzheimer's treatment for future clinical trials.

20 Aug 2024

Innovative approach to disrupt misfolding of tau proteins in neurodegenerative diseases

A spectrum of neurodegenerative diseases, including frontotemporal dementia (FTD), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are due to the accumulation of abnormal, misfolded tau proteins in the brain.

3 Apr 2024

Redefining the battle against Alzheimer's with tau-focused treatments

Researchers explore the potential of tau-targeting therapies in treating Alzheimer's disease, focusing on immunotherapies and strategies to improve their efficacy. The study dives into the complex biology of tau proteins, their modifications, and how they can be targeted to halt the progression of Alzheimer's.

29 Oct 2023

Possibility of the first fluid biomarker that reflects brain pathology in primary tauopathies

Addressing this gap in research, a recent Nature Medicine study hypothesized that 4R isoform-specific MTBR-tau species accumulate in the patient’s brain of specific subtypes of 4R tauopathies.

28 Nov 2022

New biomarker can help identify people with a primary tauopathy

Zooming in on a single disease and studying it intensely is often the most productive route to finding treatments. But there's no easy way to distinguish among people living with any of the primary tauopathies - a group of rare brain diseases marked by rapidly worsening problems with thinking and movement - because the symptoms are too similar.

24 Nov 2022

Researchers uncover new findings about the role of tau in neurodegenerative disease

Utilizing cutting-edge proteomics, researchers at the Buck Institute and elsewhere have mapped the "tau interactome" uncovering new findings about the role of tau in neurodegenerative disease. Publishing in Cell, scientists found that mutant tau impacts the function of mitochondria in human neurons.

20 Jan 2022

Study may lead to new treatments for a wide range of neurological conditions

New research published today sheds important light on how the production of a key protein in the brain is controlled, which could pave the way for new treatments for a wide range of neurological conditions.

19 May 2021

Scientists unlock crucial molecular details regarding tau's activity

Frontotemporal lobar degeneration (FTLD) is a type of dementia that appears earlier in life than Alzheimer's disease (AD).

15 Sep 2020

New test could detect abnormal forms of protein associated with tauopathies

National Institutes of Health scientists have developed an ultrasensitive new test to detect abnormal forms of the protein tau associated with uncommon types of neurodegenerative diseases called tauopathies.

16 Oct 2019

Targeting multiple proteins may be key to treat neurodegenerative disorders

Nearly all major neurodegenerative diseases - from Alzheimer's to Parkinson's - are defined and diagnosed by the presence of one of four proteins that have gone rogue: tau, amyloid-beta, alpha-synuclein, or TDP-43.

6 Jul 2018

Simple blood test may be accurate in differentiating between Parkinson's disease and APDs

A simple blood test may be as accurate as a spinal fluid test when trying to determine whether symptoms are caused by Parkinson's disease or another atypical parkinsonism disorder, according to a new study published in the February 8, 2017, online issue of Neurology, the medical journal of the American Academy of Neurology.

9 Feb 2017

Tau PET imaging in Alzheimer's disease increases opportunities for developing effective drugs

Tau PET is a new and promising imaging method for Alzheimer's disease. A case study from Lund University in Sweden now confirms that tau PET images correspond to a higher degree to actual changes in the brain. According to the researchers behind the study, this increases opportunities for developing effective drugs.

28 Sep 2016